Company

Advisors

Gracelyn Deebo
Senior Advisor for Regulatory Affairs

Gracelyn Deebo came to R-Pharm US LLC with over 30 years of pharmaceutical experience in regulatory affairs.  From 1996-2010, she worked for Eli Lilly and Company , serving in a variety of positions including global labeling, electronic submissions,  regulatory IT and regulatory policy.  Grace was recruited from Lilly to join a start-up in New Jersey, and subsequently joined R-Pharm US LLC in May, 2015.  Prior to Lilly, Grace served as head of regulatory affairs for the US affiliate of the Ipsen Group.  Her experience with start-ups include quality compliance, quality system development, vendor management, PAI readiness and CAPA resolution, as well as clinical trial execution, safety reporting and IND/NDA submissions.

Dr. Mikhail Samsonov
Chief Medical Officer, R-Pharm

He is managing and establishing all development activities in R-Pharm. With over 17 years of experience at BMS and Novartis in variety of senior / executive roles in medical affairs and clinical operations, Dr Samsonov has dedicated much of his career to building capabilities in fast-growing clinical research markets , continuous productivity improvement in well established R&D markets and developing 10 new molecules in several areas (antinfective, autoimmune, CNS, CVS, oncology, virology). He was based at several BMS offices in the US, UK, Russia and Belgium. Dr. Samsonov holds a medical degree in Internal Medicine (Moscow Medical University, Russia) , specialization in Cardiology and Ph.D. in Cardiology & Immunology (National Cardiology Centre, Moscow, Russia), completed business courses in Open University and INSEAD.

John R. Redman MD, FACP
President and CEO, Proteus Ventures LLC

Dr. John Redman is a board-certified hematologist and oncologist with over 25 years experience in the biopharmaceutical industry, primarily in clinical development but also in Medical Affairs and Regulatory.  He has supervised clinical trials or programs that have resulted in the approval of more than 15 new drugs, primarily in the field of oncology.  Recently he has been a full-time consultant to Takeda working on the development of Ninlaro.  Prior to that he was Therapeutic Area Head of Oncology at ICON Clinical Research, VP of Oncology Drug Development at Incyte Pharmaceuticals leading the early development of Jakafi and Chief Medical Officer of Celator Pharmaceuticals.  He has also been the Therapeutic Area Head of Oncology at PharmaNet where he was medical monitor for the registration studies of Revlimid and Erbitux, VP at Duquesne Capital Management, biotechnology equity research analyst at Credit Suisse First Boston and Senior Director at Wyeth Pharmaceuticals (supervising Mylotarg, Rapamune and multiple other drugs).

John is a graduate of Bowdoin College (AB), the University of Vermont College of Medicine (MD) and the Wharton School of the University of Pennsylvania (MBA).  Internal Medicine residency was completed at Cornell Cooperating Hospitals in New York City and a Hematology-Oncology fellowship was done at Memorial Sloan-Kettering Cancer Center in New York City.  Following fellowship he was an Assistant Professor in the Hematology Department at MD Anderson Cancer Center in Houston, TX.